How Antibiotics Kill Bacteria

Bacteria Are Not Human Cells

Antibiotics can kill bacteria without (usually) harming human cells because bacteria differ from our cells in fundamental ways. Human cells are eukaryotic — they have a nucleus and complex internal machinery. Bacteria are prokaryotic — they have different cell wall chemistry, different ribosomes (protein factories), and different DNA-replication enzymes.

Antibiotics exploit these differences, targeting bacterial structures that either don't exist in human cells or are different enough that the drug doesn't affect ours. This is called selective toxicity: the drug is toxic to the pathogen but relatively safe for the host.

Cell Wall Disruption: Penicillins and Cephalosporins

Bacteria have a rigid outer wall made of a mesh-like polymer called peptidoglycan. This wall maintains the bacterium's shape and withstands the internal pressure that would otherwise cause the cell to burst. Human cells have no cell wall — we have flexible plasma membranes — so drugs targeting the cell wall are inherently selective.

Penicillins (ampicillin, amoxicillin, piperacillin) and cephalosporins (cephalexin, ceftriaxone, cefepime) both belong to the beta-lactam class. They work by binding to enzymes called penicillin-binding proteins (PBPs) that bacteria use to build and repair peptidoglycan. With PBPs blocked, the bacteria cannot maintain their cell wall. As they try to divide, the wall weakens and bacteria burst open — a process called lysis.

Vancomycin works differently but targets the same wall: it physically grabs the peptidoglycan building blocks before they can be assembled, blocking wall synthesis without binding to PBPs. This is why vancomycin works against some bacteria (like MRSA) that are resistant to penicillins.

Protein Synthesis Inhibitors

Ribosomes are molecular machines that assemble proteins from genetic instructions. Bacterial ribosomes (called 70S) are structurally different from human ribosomes (80S), allowing antibiotics to block bacterial protein synthesis without affecting ours.

• Macrolides (azithromycin, clarithromycin, erythromycin) bind to the 50S subunit of the bacterial ribosome, blocking the exit tunnel through which newly made proteins normally thread out. The ribosome stalls.
• Tetracyclines (doxycycline, minocycline) bind to the 30S ribosomal subunit, blocking the amino acid delivery vehicle (aminoacyl-tRNA) from docking — so no new amino acids can be added to the growing protein chain.
• Aminoglycosides (gentamicin, tobramycin) also target the 30S subunit but cause the ribosome to misread genetic instructions, producing malformed proteins that are toxic to the bacterium.
• Clindamycin and chloramphenicol target the 50S subunit, each with slightly different binding sites than macrolides.

DNA and RNA-Targeted Antibiotics

Some antibiotics interfere with how bacteria copy and read their genetic information.

Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) inhibit two enzymes bacteria need to manage DNA topology: DNA gyrase and topoisomerase IV. When these enzymes are blocked, DNA strands get tangled and broken during replication, and the bacterium cannot divide. Because human cells have different versions of these enzymes, fluoroquinolones primarily target bacteria — though at high doses or in people with certain genetic variants, some human cell effects can occur.

Rifampin targets bacterial RNA polymerase — the enzyme that transcribes DNA into RNA. With RNA polymerase blocked, bacteria cannot produce any proteins at all. Rifampin is used in tuberculosis treatment and against certain resistant infections.

Metronidazole is activated inside anaerobic (oxygen-hating) bacteria into reactive molecules that break DNA strands, killing the cell.

Bactericidal vs. Bacteriostatic

Antibiotics can be classified by whether they kill bacteria outright (bactericidal) or merely stop them from reproducing while the immune system finishes the job (bacteriostatic).

The distinction matters in patients with weakened immune systems (cancer, HIV, post-transplant). If the immune system can't do its part, bacteriostatic antibiotics may be insufficient and bactericidal drugs are preferred.

How Antibiotic Resistance Develops

Antibiotic resistance occurs when bacteria evolve mechanisms to survive exposure to an antibiotic. Common strategies bacteria use:

• Enzyme degradation: Bacteria produce enzymes that destroy the antibiotic. Beta-lactamase enzymes, for example, break the core ring structure of penicillins and cephalosporins, rendering them inactive. Extended-spectrum beta-lactamases (ESBLs) can inactivate most of this class.
• Efflux pumps: Bacteria pump the antibiotic out of the cell before it can act.
• Target modification: The bacterium changes the structure of the target (e.g., altering PBPs so beta-lactams no longer bind — the mechanism behind MRSA).
• Reduced permeability: Bacteria alter their outer membrane to prevent the antibiotic from entering.

Resistance genes can be shared between bacteria — even different species — through a process called horizontal gene transfer. This is how resistance spreads rapidly through bacterial populations.

efficacyEfficacy

The maximum therapeutic effect a drug can produce, regardless of the dose given. A drug with higher efficacy can achieve a greater maximum response than one with lower efficacy, even if the latter is

-and-why-finishing-the-course-matters">Efficacy and Why Finishing the Course Matters

Not all bacteria in an infection are identical. Natural variation means a small number may have slight mutations that make them marginally better at surviving the antibiotic. When a course is stopped early because you feel better, the most susceptible bacteria have been killed — but the slightly more resistant survivors remain and multiply, potentially passing on their resistance traits.

Completing the full antibiotic course is not about "killing all the bacteria" — your immune system handles the last remnants. It is about preventing selection of resistant mutants during the treatment period.

The concept of antibiotic efficacy is also time- and concentration-dependent. Some antibiotics (fluoroquinolones, aminoglycosides) work best when peak concentration is very high relative to the bacteria's minimum inhibitory concentration (MIC). Others (penicillins, cephalosporins) work best when levels remain above the MIC for as long as possible. Dosing schedules are designed to optimize whichever pattern is most effective.

Key Takeaways

• Antibiotics exploit structural differences between bacterial and human cells, targeting cell walls, ribosomes, or DNA enzymes that bacteria have but we do not.
• Beta-lactams (penicillins, cephalosporins) destroy the bacterial cell wall; macrolides, tetracyclines, and aminoglycosides block protein synthesis; fluoroquinolones disrupt DNA replication.
• Bactericidal antibiotics kill bacteria; bacteriostatic antibiotics stop their growth — the distinction matters most in immunocompromised patients.
• Antibiotic resistance develops through enzyme degradation, efflux pumps, target mutations, or reduced drug uptake — and spreads between bacteria through gene sharing.
• Finishing a full antibiotic course prevents selection of resistant survivors, even after you feel better.